How to Find Hidden Specialty Pharmacy Deals – Broker Secrets Explained

In this episode the hosts dig into a $7.1 M cash‑price listing for a specialty pharmacy in Beverly Hills — evaluating its 1.49 M EBITDA, market position and regulatory complexity to see whether it’s a viable acquisition. Business Listing – https://www.bizbuysell.com/business-opportunity/specialty-medical-pharmacy-in-prime-southern-california-location/2445305/ Welcome to Acquisitions Anonymous – the #1 podcast for small business M&A. Every week, we break down businesses for sale and talk about buying, operating, and growing them. Subscribe for more episodes: https://www.youtube.com/@AcquisitionsAnonymousPodcast?sub_confirmation=1 Subscribe to our Newsletter: https://www.acquanon.com/newsletter Connect with us on Social Media: Twitter: https://twitter.com/acquanon LinkedIn: https://www.linkedin.com/company/acquanon 👋 Follow the Hosts Michael Girdley – Entrepreneur & investor. Twitter: https://twitter.com/girdley Bill D’Alessandro – CEO of Elements Brands. Twitter: https://twitter.com/BillDA Heather Endresen – SBA lending expert & advisor. Twitter: https://twitter.com/EndresenHeather Mills Snell – Small business investor & advisor. Twitter: https://twitter.com/thegeneralmills 💰 Sponsored by: Tonnesen Accounting Services - Tonnesen provides full quality of earnings reports trusted by buyers, lenders, and brokers on over $500 million in deals each year. Fast, detailed, and affordable. Visit tonnesenaccountingservices.com or connect with Josh Tonnesen on LinkedIn for a free consult. Capital Pad – A platform connecting accredited investors with vetted small business acquisition deals. Discover exclusive opportunities at https://capitalpad.com This episode of Acquisitions Anonymous breaks down a real‑world potential buy of a specialty (medical) pharmacy based in Beverly Hills, California. The listing claims a 2025 expected revenue of about $6.2 M with $1.49 M in EBITDA/SDE, monthly rent around $9,167, and an asking price of $7.1 M — roughly 4.75× trailing earnings. The sellers are motivated by acute health issues and retirement, which introduces urgency. The hosts explore both the upside — a long‑established business in a wealthy market, high margins, and niche specialty‑pharmacy demand — and the downsides: regulatory/licensure hurdles, dependence on skilled pharmacists, insurance/payer access challenges, and the uncertainty of consistency in earnings. Key Highlights: - Asking price: $7.1 M cash, with stated EBITDA/SDE of $1.49 M → ~4.75× multiple. - Business profile: Long‑established (since ~1980), located in affluent Beverly Hills, servicing specialty prescriptions (potentially high‑cost biologics, pain, immunology, chemo) rather than typical retail offerings. Specialty pharmacies serve high‑cost, complex, or chronic therapies requiring “high‑touch” care and coordination. Wikipedia - Opportunity: High margins (claimed ~25%) — above what might be expected for a typical low‑margin compounding pharmacy. If true and paired with stable payer contracts and referral relationships, this could be a strong cash-flow business with recurring demand. - Risks: Regulatory/licensure risk under the California pharmacy law: any change in ownership or control requires approval by the board before the transaction can close. - Execution risk: Because the seller is reportedly ill and likely a “forced seller,” there may be pressure to close quickly — which compresses time for due diligence on payer contracts, referral sources, license transfers, and underlying quality-of-earnings. That urgency could mean accepting a lower price or encountering unexpected liabilities.